Vimarsana
Biggest News Aggregation in the World

Page 2 - Bertram Pitt News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Bertram Pitt. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Bertram Pitt Today - Breaking & Trending Today

Cardiologists making strides in COVID-19 research - Vimarsana News

Cardiologists making strides in COVID-19 research

Cardiology Today | COVID-19 is predominantly considered an infectious and respiratory disease, but it is intertwined with the CV system as well. That means cardiologists have a lot to contribute to battle it, especially in the area of pathophysiology.Because COVID-19 is often considered an ICU issue and an infectious disease, cardiologists have at times been left on the sideline during the pandemic. But we now know

Source: healio.com
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Q4 2022 Earnings Call Transcript - Vimarsana News

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Q4 2022 Earnings Call Transcript

Operator: Good afternoon, and welcome to the Lexicon Pharmaceuticals Fourth Quarter 2022 Earnings Conference Call. All participants will be in a listen-only mode.

Ocedurenone (KBP-5074) Featured at ASN Kidney Week: Ocedurenone is a Potential New Treatment Option for Patients with Uncontrolled or Resistant Hypertension and Advanced CKD - Vimarsana News

Ocedurenone (KBP-5074) Featured at ASN Kidney Week: Ocedurenone is a Potential New Treatment Option for Patients with Uncontrolled or Resistant Hypertension and Advanced CKD

/PRNewswire/ -- KBP Biosciences PTE. Ltd. ("KBP Biosciences" or the "Company"), a clinical-stage biotechnology company dedicated to research, development, and...

KBP Biosciences: Ocedurenone (KBP-5074) Featured at ASN Kidney Week: Ocedurenone is a Potential New Treatment Option for Patients with Uncontrolled or Resistant Hypertension and Advanced CKD - Vimarsana News

KBP Biosciences: Ocedurenone (KBP-5074) Featured at ASN Kidney Week: Ocedurenone is a Potential New Treatment Option for Patients with Uncontrolled or Resistant Hypertension and Advanced CKD

Hepatic Impairment and Drug-Drug Interaction Study Results Presented PRINCETON, N.J., Jan. 6, 2023 /PRNewswire/ -- KBP Biosciences PTE. Ltd. ("KBP Biosciences" or the "Company"), a clinical-stage

Ocedurenone (KBP-5074) Featured at ASN Kidney Week: Ocedurenone is a Potential New Treatment Option for Patients with Uncontrolled or Resistant Hypertension and Advanced CKD - Vimarsana News

Ocedurenone (KBP-5074) Featured at ASN Kidney Week: Ocedurenone is a Potential New Treatment Option for Patients with Uncontrolled or Resistant Hypertension and Advanced CKD

Ocedurenone (KBP-5074) Featured at ASN Kidney Week: Ocedurenone is a Potential New Treatment Option for Patients with Uncontrolled or Resistant Hypertension and Advanced CKD - read this article along with other careers information, tips and advice on BioSpace